1005-26-1

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Pyrimidinediamine, N4,N4-dimethyl(9CI) is used as an intermediate in the synthesis of various pharmaceuticals for its ability to form complex molecules that can target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Pyrimidinediamine, N4,N4-dimethyl(9CI) is employed as a precursor in the development of agrochemicals, contributing to the creation of compounds that can enhance crop protection and yield.
Used in Organic Chemistry Research and Development:
2,4-Pyrimidinediamine, N4,N4-dimethyl(9CI) is utilized as a building block in organic chemistry for the formation of more complex molecules, facilitating the research and development of new drugs and organic materials.
Used in Chemical Synthesis:
2,4-Pyrimidinediamine, N4,N4-dimethyl(9CI) is used as a reagent in chemical synthesis processes, enabling the production of a wide range of organic compounds for various applications.

Upstream product

• 3993-78-0 2-amino-4-chloropyrimidine 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 

Relevant academic research and scientific papers

Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography

Aggregates of tau and beta amyloid (Aβ) plaques constitute the histopathological hallmarks of Alzheimer's disease and are prominent targets for novel therapeutics as well as for biomarkers for diagnostic in vivo imaging. In recent years much attention has been devoted to the discovery and development of new PET tracers to image tau aggregates in the living human brain. Access to a selective PET tracer to image and quantify tau aggregates represents a unique tool to support the development of any novel therapeutic agent targeting pathological forms of tau. The objective of the study described herein was to identify such a novel radiotracer. As a result of this work, we discovered three novel PET tracers (2-(4-[11C]methoxyphenyl)imidazo[1,2-a]pyridin-7-amine 7 ([11C]RO6924963), N-[11C]methyl-2-(3-methylphenyl)imidazo[1,2-a]pyrimidin-7-amine 8 ([11C]RO6931643), and [18F]2-(6-fluoropyridin-3-yl)pyrrolo[2,3-b:4,5-c′]dipyridine 9 ([18F]RO6958948)) with high affinity for tau neurofibrillary tangles, excellent selectivity against Aβ plaques, and appropriate pharmacokinetic and metabolic properties in mice and non-human primates.

Design, synthesis and biological evaluation of 2-methyl-(1,1′-biphenyl)-pyrimidine conjugates

Small molecule inhibitors of biphenyl structure as core backbone have shown a significant effect on PD-1/PD-L1 axis, and 2-amino-pyrimidine structure is a promising privileged scaffold in medicinal chemistry and drug discovery. We designed by combination principles and synthesized 27 novel compounds with N-((2-methyl-[1,1′-biphenyl]-3-yl)methyl)pyrimidin-2-amine as a basic skeletal structure, and their anti-cancer activity was evaluated. Among compounds, 15a-d and 16b displayed strong anti-cancer effects on 9 tested cancer cell lines, in particular, the 16b did the highest inhibitive activity, but against HepG2 cells, and possessed the lowest IC50 value of 2.08 μΜ towards HT-29 cells.

Biphenyl-pyrimidine conjugate as well as preparation method and application thereof

The invention discloses a biphenyl-pyrimidine conjugate as well as a preparation method and application thereof. The structural general formula of the biphenyl-pyrimidine conjugate is shown as a formula (I) (See the specification), wherein R1 is selected from H, halogen, C1-C3 fluoroalkyl, morpholinyl, piperazinyl, pyrrolidinyl or dimethylamino, and R2 is selected from halogen, dimethylamino, diethylamino, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, N-(3-dimethylamino) propyl, N-(3-diethylamino) propyl, N-(1-(3-aminopropyl) pyrrolidinyl), N-(1-(3-aminopropyl) piperidinyl) or N-(1-(3-aminopropyl) morpholinyl). Through homogeneous time-resolved fluorescence experiments, it is found that the compound provided by the invention can inhibit the interaction of PD-1/PD-L1 and restore theactivity of T cells, so that the compound has an anti-tumor effect. The invention provides important reference value for discovery of new anti-tumor small molecule drugs, especially for promotion of research and development of biphenyl-pyrimidine conjugate targeted PD-1/PD-L1 clinical drugs.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS

The present invention relates to compounds of general formula (I) wherein R1 is phenyl, optionally substituted by one or two substituents, selected from 3H, halogen, lower alkyl, di-methyl-amino, NHC(O)-lower alkyl, C(O)O-lower alkyl, lower alkoxy, OC(3H)3, O11CH3, OCH2CH218F, lower alkoxy substituted by halogen, hydroxy, lower alkyl substituted by hydroxy, S-lower alkyl, or by a heterocyclyl group; or is benzo[d][l,3]dioxol-5-yl, 2,3-dihydrobenzo[b][l,4]dioxin-6-yl, indolin-2-one, or is heteroaryl, selected from the group consisting of thiophenyl, benzofuranyl, benzothiophenyl, pyrazinyl, or benzothiazolyl; R2 is hydrogen, lower alkyl or lower alkyl substituted by halogen; R3 is lower alkyl, C(3H)3, 11CH3, lower alkyl substituted by halogen, -(CH2)2-O-lower alkyl substituted by halogen or cycloalkyl; or R2 and R3 form together with the N-atom to which they are attach a ring containing -CH2CH2CHRCH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2-NR-CH2CH2-, -CH2CH2-O-CH2CH2-, -CH2CH2CHRCH2-, -CH2CHRCH2- or (A); R is hydrogen, halogen, lower alkyl substituted by halogen or lower alkoxy; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer' s disease.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.